Lower Medical Costs Aid UNH Recovery, but Durability Remains Unproven

What happened

The Zacks article highlights that UnitedHealth's earnings recovery is driven by lower medical costs, but questions its sustainability given rising commercial cost trends and upcoming 2027 pricing decisions. This aligns with our existing analysis that the recovery is margin-led and partly supported by favorable reserve development, as seen in 2Q26 where MCR improved to 86.7% but included $860M of prior-period development. The article adds little new information but reinforces the key risk: commercial medical cost trend remains above 11%, and Medicare Advantage enrollment continues to shrink. Our deep value assessment already accounts for these factors, maintaining a Wait rating as the stock trades at 26.3x earnings with limited upside if organic growth does not return. Overall, the news is consistent with our view that the recovery is not yet proven durable, and we continue to monitor underlying cost trends and membership stabilization.

Implication

Current valuation already prices in a successful recovery, leaving limited upside if cost trends revert or favorable reserve development normalizes. Watch for 3Q26 and 4Q26 MCR versus the 88.1% full-year guide, as reliance on reserve releases would undermine the quality of earnings. Medicare Advantage membership continues to decline, and the 2027 rate increase may not fully offset competitive losses, so monitor AEP results for signs of stabilization. Optum volumes are also shrinking, indicating the recovery is not yet broad-based across the enterprise. We maintain a Wait rating, with attractive entry near $365 and trim above $445, as the risk-reward remains balanced at current levels.

Thesis delta

The article does not materially change our thesis; it echoes existing concerns about sustainability of medical cost improvements and membership attrition. Our view remains that the recovery is margin-led and partly reserve-supported, with upside limited until organic growth improves. No change to rating or price targets.